Tagged with Europe,

Medicines for Europe In the wake of the publication of Medicines for Europe’s Lessons Learned from COVID-19 policy paper, Christoph Stoller & Adrian van den Hoven outline the European generics, biosimilar and value-added-medicines industry’s rapid and comprehensive response to the COVID-19 crisis as well as the potential long-term shifts in European pharmaceutical policy…

Belgium Alexander Alonso, general manager of medtech giant BD’s operations in Belgium, the Netherlands, and Luxembourg outlines the company’s extensive footprint in the region, how it has rapidly mobilised in the fight against COVID-19, and the market access situation for innovative medtech solutions in Belgium today.   In Benelux there is…

Europe The European Medicines Agency (EMA), Europe’s regulatory body for medicines, has nominated Irish candidate Emer Cooke to as its new executive director at a crucial time for the agency as its powers and priorities shift in the wake of the COVID-19 crisis.   If Cooke accepts and gives an official…

Italy Below we present recent news from Italy’s biopharma industry, including the recent acquisition of Stemline Therapeutics by Menarini, research collaboration between Italy and China, labelling regulations, a new biotech sector report and new studies on antibodies against Covid-19.   Menarini gains presence in US oncology market with acquisition of Stemline…

Italy Menarini Group, the largest Italian pharmaceutical company by turnover, has made its first move into the US oncology market through the acquisition of Stemline Therapeutics.   The deal, said to be worth USD 677 million, was announced on 4 May 2020 and completed on 10 June. The acquisition of Stemline,…

Cell & Gene Therapy The cell and gene therapy market was valued at USD 6 billion in 2017 and is projected to exceed USD 35 billion in value by 2026. Moreover, these therapies stand to redefine medical paradigms by providing treatments for previously incurable diseases and usher in a new era of precise and…

Europe In a recent exclusive conversation with PharmaBoardroom, Nathalie Moll, director general of the European Federation of Pharmaceutical Industries & Associations (EFPIA), laid out the ways in which the European innovative pharma industry has come together to solve some of the most pressing issues around COVID-19, and how a more inter-connected…

Europe Emmanuel Macron and Angela Merkel recently put their heads together to come up with a health strategy that would ensure greater European access to innovative medicines and COVID-19 treatments.   The so-called “power couple” – German chancellor Angela Merkel and French president Emmanuel Macron –  presented a jointly developed five-point…

Europe The EFPIA’s Nathalie Moll gives an insight into the work underway across the European pharmaceutical industry to battle COVID-19 in terms of supporting organisations on the ground, ensuring the supply of medicines, and working on the research and development of treatments, vaccines, and diagnostics. Moll also outlines the vital importance…

Coronavirus In a recent interview with Financial Times, Sanofi CEO Paul Hudson set out to clarify some recent comments that the US would get priority access to a COVID-19 vaccine. He explained the firm’s collaboration with US research group BARDA and underscored that Sanofi is committed to bringing vaccines to all…

Europe A full list of EMA ATMP approvals. Made with Visme Infographic Maker  

EFPIA The European Commission recently announced a new industrial strategy and pharmaceutical roadmap, largely focused on revising legislation dating back nearly two decades, with the aim of laying out a concrete plan by the end of 2020. The commission’s priority is to revitalize medical innovation in Europe, a chief concern voiced…